Global Spinal Muscular Atrophy Medicine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Spinal Muscular Atrophy Medicine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Spinal Muscular Atrophy Medicine industry chain, the market status of Hospital (LMI-070, ND-602), Clinic (LMI-070, ND-602), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Spinal Muscular Atrophy Medicine.
Regionally, the report analyzes the Spinal Muscular Atrophy Medicine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Spinal Muscular Atrophy Medicine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Spinal Muscular Atrophy Medicine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Spinal Muscular Atrophy Medicine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Pcs), revenue generated, and market share of different by Type (e.g., LMI-070, ND-602).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Spinal Muscular Atrophy Medicine market.
Regional Analysis: The report involves examining the Spinal Muscular Atrophy Medicine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Spinal Muscular Atrophy Medicine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Spinal Muscular Atrophy Medicine:
Company Analysis: Report covers individual Spinal Muscular Atrophy Medicine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Spinal Muscular Atrophy Medicine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Spinal Muscular Atrophy Medicine. It assesses the current state, advancements, and potential future developments in Spinal Muscular Atrophy Medicine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Spinal Muscular Atrophy Medicine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Spinal Muscular Atrophy Medicine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Spinal Muscular Atrophy Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Spinal Muscular Atrophy Medicine, with price, sales, revenue and global market share of Spinal Muscular Atrophy Medicine from 2019 to 2024.
Chapter 3, the Spinal Muscular Atrophy Medicine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Spinal Muscular Atrophy Medicine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Spinal Muscular Atrophy Medicine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Spinal Muscular Atrophy Medicine.
Chapter 14 and 15, to describe Spinal Muscular Atrophy Medicine sales channel, distributors, customers, research findings and conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Spinal Muscular Atrophy Medicine industry chain, the market status of Hospital (LMI-070, ND-602), Clinic (LMI-070, ND-602), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Spinal Muscular Atrophy Medicine.
Regionally, the report analyzes the Spinal Muscular Atrophy Medicine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Spinal Muscular Atrophy Medicine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Spinal Muscular Atrophy Medicine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Spinal Muscular Atrophy Medicine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Pcs), revenue generated, and market share of different by Type (e.g., LMI-070, ND-602).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Spinal Muscular Atrophy Medicine market.
Regional Analysis: The report involves examining the Spinal Muscular Atrophy Medicine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Spinal Muscular Atrophy Medicine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Spinal Muscular Atrophy Medicine:
Company Analysis: Report covers individual Spinal Muscular Atrophy Medicine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Spinal Muscular Atrophy Medicine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Spinal Muscular Atrophy Medicine. It assesses the current state, advancements, and potential future developments in Spinal Muscular Atrophy Medicine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Spinal Muscular Atrophy Medicine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Spinal Muscular Atrophy Medicine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- LMI-070
- ND-602
- NT-1654
- Nusinersen
- NXD-30001
- Others
- Hospital
- Clinic
- Others
- Astellas Pharma Inc.
- AveXis, Inc.
- Bioblast Pharma Ltd.
- Cytokinetics, Inc. 24
- F. Hoffmann-La Roche Ltd.
- Genethon
- Genzyme Corporation
- GMP-Orphan SAS
- Ionis Pharmaceuticals, Inc.
- Longevity Biotech, Inc
- Neurodyn Inc.
- Neurotune AG
- Novartis AG
- Sarepta Therapeutics, Inc.
- Voyager Therapeutics, Inc.
- Vybion, Inc.
- WAVE Life Sciences Ltd.
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Spinal Muscular Atrophy Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Spinal Muscular Atrophy Medicine, with price, sales, revenue and global market share of Spinal Muscular Atrophy Medicine from 2019 to 2024.
Chapter 3, the Spinal Muscular Atrophy Medicine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Spinal Muscular Atrophy Medicine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Spinal Muscular Atrophy Medicine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Spinal Muscular Atrophy Medicine.
Chapter 14 and 15, to describe Spinal Muscular Atrophy Medicine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Spinal Muscular Atrophy Medicine Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 LMI-070
1.3.3 ND-602
1.3.4 NT-1654
1.3.5 Nusinersen
1.3.6 NXD-30001
1.3.7 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Spinal Muscular Atrophy Medicine Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Spinal Muscular Atrophy Medicine Market Size & Forecast
1.5.1 Global Spinal Muscular Atrophy Medicine Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Spinal Muscular Atrophy Medicine Sales Quantity (2019-2030)
1.5.3 Global Spinal Muscular Atrophy Medicine Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Astellas Pharma Inc.
2.1.1 Astellas Pharma Inc. Details
2.1.2 Astellas Pharma Inc. Major Business
2.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product and Services
2.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Astellas Pharma Inc. Recent Developments/Updates
2.2 AveXis, Inc.
2.2.1 AveXis, Inc. Details
2.2.2 AveXis, Inc. Major Business
2.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 AveXis, Inc. Recent Developments/Updates
2.3 Bioblast Pharma Ltd.
2.3.1 Bioblast Pharma Ltd. Details
2.3.2 Bioblast Pharma Ltd. Major Business
2.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Bioblast Pharma Ltd. Recent Developments/Updates
2.4 Cytokinetics, Inc.
2.4.1 Cytokinetics, Inc. 24 Details
2.4.2 Cytokinetics, Inc. 24 Major Business
2.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product and Services
2.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Cytokinetics, Inc. 24 Recent Developments/Updates
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
2.6 Genethon
2.6.1 Genethon Details
2.6.2 Genethon Major Business
2.6.3 Genethon Spinal Muscular Atrophy Medicine Product and Services
2.6.4 Genethon Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Genethon Recent Developments/Updates
2.7 Genzyme Corporation
2.7.1 Genzyme Corporation Details
2.7.2 Genzyme Corporation Major Business
2.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product and Services
2.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Genzyme Corporation Recent Developments/Updates
2.8 GMP-Orphan SAS
2.8.1 GMP-Orphan SAS Details
2.8.2 GMP-Orphan SAS Major Business
2.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product and Services
2.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 GMP-Orphan SAS Recent Developments/Updates
2.9 Ionis Pharmaceuticals, Inc.
2.9.1 Ionis Pharmaceuticals, Inc. Details
2.9.2 Ionis Pharmaceuticals, Inc. Major Business
2.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
2.10 Longevity Biotech, Inc
2.10.1 Longevity Biotech, Inc Details
2.10.2 Longevity Biotech, Inc Major Business
2.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product and Services
2.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Longevity Biotech, Inc Recent Developments/Updates
2.11 Neurodyn Inc.
2.11.1 Neurodyn Inc. Details
2.11.2 Neurodyn Inc. Major Business
2.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product and Services
2.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Neurodyn Inc. Recent Developments/Updates
2.12 Neurotune AG
2.12.1 Neurotune AG Details
2.12.2 Neurotune AG Major Business
2.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product and Services
2.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Neurotune AG Recent Developments/Updates
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product and Services
2.13.4 Novartis AG Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Novartis AG Recent Developments/Updates
2.14 Sarepta Therapeutics, Inc.
2.14.1 Sarepta Therapeutics, Inc. Details
2.14.2 Sarepta Therapeutics, Inc. Major Business
2.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Sarepta Therapeutics, Inc. Recent Developments/Updates
2.15 Voyager Therapeutics, Inc.
2.15.1 Voyager Therapeutics, Inc. Details
2.15.2 Voyager Therapeutics, Inc. Major Business
2.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Voyager Therapeutics, Inc. Recent Developments/Updates
2.16 Vybion, Inc.
2.16.1 Vybion, Inc. Details
2.16.2 Vybion, Inc. Major Business
2.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Vybion, Inc. Recent Developments/Updates
2.17 WAVE Life Sciences Ltd.
2.17.1 WAVE Life Sciences Ltd. Details
2.17.2 WAVE Life Sciences Ltd. Major Business
2.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 WAVE Life Sciences Ltd. Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SPINAL MUSCULAR ATROPHY MEDICINE BY MANUFACTURER
3.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Manufacturer (2019-2024)
3.2 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2019-2024)
3.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Spinal Muscular Atrophy Medicine by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Spinal Muscular Atrophy Medicine Manufacturer Market Share in 2023
3.4.2 Top 6 Spinal Muscular Atrophy Medicine Manufacturer Market Share in 2023
3.5 Spinal Muscular Atrophy Medicine Market: Overall Company Footprint Analysis
3.5.1 Spinal Muscular Atrophy Medicine Market: Region Footprint
3.5.2 Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
3.5.3 Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Spinal Muscular Atrophy Medicine Market Size by Region
4.1.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2030)
4.1.2 Global Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2030)
4.1.3 Global Spinal Muscular Atrophy Medicine Average Price by Region (2019-2030)
4.2 North America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.3 Europe Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.4 Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.5 South America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.6 Middle East and Africa Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
5.2 Global Spinal Muscular Atrophy Medicine Consumption Value by Type (2019-2030)
5.3 Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
6.2 Global Spinal Muscular Atrophy Medicine Consumption Value by Application (2019-2030)
6.3 Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
7.2 North America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
7.3 North America Spinal Muscular Atrophy Medicine Market Size by Country
7.3.1 North America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
7.3.2 North America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
8.2 Europe Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
8.3 Europe Spinal Muscular Atrophy Medicine Market Size by Country
8.3.1 Europe Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
8.3.2 Europe Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Region
9.3.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
10.2 South America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
10.3 South America Spinal Muscular Atrophy Medicine Market Size by Country
10.3.1 South America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
10.3.2 South America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Spinal Muscular Atrophy Medicine Market Size by Country
11.3.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Spinal Muscular Atrophy Medicine Market Drivers
12.2 Spinal Muscular Atrophy Medicine Market Restraints
12.3 Spinal Muscular Atrophy Medicine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Spinal Muscular Atrophy Medicine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Spinal Muscular Atrophy Medicine
13.3 Spinal Muscular Atrophy Medicine Production Process
13.4 Spinal Muscular Atrophy Medicine Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Spinal Muscular Atrophy Medicine Typical Distributors
14.3 Spinal Muscular Atrophy Medicine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Spinal Muscular Atrophy Medicine Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 LMI-070
1.3.3 ND-602
1.3.4 NT-1654
1.3.5 Nusinersen
1.3.6 NXD-30001
1.3.7 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Spinal Muscular Atrophy Medicine Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Spinal Muscular Atrophy Medicine Market Size & Forecast
1.5.1 Global Spinal Muscular Atrophy Medicine Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Spinal Muscular Atrophy Medicine Sales Quantity (2019-2030)
1.5.3 Global Spinal Muscular Atrophy Medicine Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Astellas Pharma Inc.
2.1.1 Astellas Pharma Inc. Details
2.1.2 Astellas Pharma Inc. Major Business
2.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product and Services
2.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Astellas Pharma Inc. Recent Developments/Updates
2.2 AveXis, Inc.
2.2.1 AveXis, Inc. Details
2.2.2 AveXis, Inc. Major Business
2.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 AveXis, Inc. Recent Developments/Updates
2.3 Bioblast Pharma Ltd.
2.3.1 Bioblast Pharma Ltd. Details
2.3.2 Bioblast Pharma Ltd. Major Business
2.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Bioblast Pharma Ltd. Recent Developments/Updates
2.4 Cytokinetics, Inc.
2.4.1 Cytokinetics, Inc. 24 Details
2.4.2 Cytokinetics, Inc. 24 Major Business
2.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product and Services
2.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Cytokinetics, Inc. 24 Recent Developments/Updates
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
2.6 Genethon
2.6.1 Genethon Details
2.6.2 Genethon Major Business
2.6.3 Genethon Spinal Muscular Atrophy Medicine Product and Services
2.6.4 Genethon Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Genethon Recent Developments/Updates
2.7 Genzyme Corporation
2.7.1 Genzyme Corporation Details
2.7.2 Genzyme Corporation Major Business
2.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product and Services
2.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Genzyme Corporation Recent Developments/Updates
2.8 GMP-Orphan SAS
2.8.1 GMP-Orphan SAS Details
2.8.2 GMP-Orphan SAS Major Business
2.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product and Services
2.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 GMP-Orphan SAS Recent Developments/Updates
2.9 Ionis Pharmaceuticals, Inc.
2.9.1 Ionis Pharmaceuticals, Inc. Details
2.9.2 Ionis Pharmaceuticals, Inc. Major Business
2.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
2.10 Longevity Biotech, Inc
2.10.1 Longevity Biotech, Inc Details
2.10.2 Longevity Biotech, Inc Major Business
2.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product and Services
2.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Longevity Biotech, Inc Recent Developments/Updates
2.11 Neurodyn Inc.
2.11.1 Neurodyn Inc. Details
2.11.2 Neurodyn Inc. Major Business
2.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product and Services
2.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Neurodyn Inc. Recent Developments/Updates
2.12 Neurotune AG
2.12.1 Neurotune AG Details
2.12.2 Neurotune AG Major Business
2.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product and Services
2.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Neurotune AG Recent Developments/Updates
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product and Services
2.13.4 Novartis AG Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Novartis AG Recent Developments/Updates
2.14 Sarepta Therapeutics, Inc.
2.14.1 Sarepta Therapeutics, Inc. Details
2.14.2 Sarepta Therapeutics, Inc. Major Business
2.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Sarepta Therapeutics, Inc. Recent Developments/Updates
2.15 Voyager Therapeutics, Inc.
2.15.1 Voyager Therapeutics, Inc. Details
2.15.2 Voyager Therapeutics, Inc. Major Business
2.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Voyager Therapeutics, Inc. Recent Developments/Updates
2.16 Vybion, Inc.
2.16.1 Vybion, Inc. Details
2.16.2 Vybion, Inc. Major Business
2.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Vybion, Inc. Recent Developments/Updates
2.17 WAVE Life Sciences Ltd.
2.17.1 WAVE Life Sciences Ltd. Details
2.17.2 WAVE Life Sciences Ltd. Major Business
2.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 WAVE Life Sciences Ltd. Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SPINAL MUSCULAR ATROPHY MEDICINE BY MANUFACTURER
3.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Manufacturer (2019-2024)
3.2 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2019-2024)
3.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Spinal Muscular Atrophy Medicine by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Spinal Muscular Atrophy Medicine Manufacturer Market Share in 2023
3.4.2 Top 6 Spinal Muscular Atrophy Medicine Manufacturer Market Share in 2023
3.5 Spinal Muscular Atrophy Medicine Market: Overall Company Footprint Analysis
3.5.1 Spinal Muscular Atrophy Medicine Market: Region Footprint
3.5.2 Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
3.5.3 Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Spinal Muscular Atrophy Medicine Market Size by Region
4.1.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2030)
4.1.2 Global Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2030)
4.1.3 Global Spinal Muscular Atrophy Medicine Average Price by Region (2019-2030)
4.2 North America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.3 Europe Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.4 Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.5 South America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
4.6 Middle East and Africa Spinal Muscular Atrophy Medicine Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
5.2 Global Spinal Muscular Atrophy Medicine Consumption Value by Type (2019-2030)
5.3 Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
6.2 Global Spinal Muscular Atrophy Medicine Consumption Value by Application (2019-2030)
6.3 Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
7.2 North America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
7.3 North America Spinal Muscular Atrophy Medicine Market Size by Country
7.3.1 North America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
7.3.2 North America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
8.2 Europe Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
8.3 Europe Spinal Muscular Atrophy Medicine Market Size by Country
8.3.1 Europe Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
8.3.2 Europe Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Region
9.3.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
10.2 South America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
10.3 South America Spinal Muscular Atrophy Medicine Market Size by Country
10.3.1 South America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
10.3.2 South America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Spinal Muscular Atrophy Medicine Market Size by Country
11.3.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Spinal Muscular Atrophy Medicine Market Drivers
12.2 Spinal Muscular Atrophy Medicine Market Restraints
12.3 Spinal Muscular Atrophy Medicine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Spinal Muscular Atrophy Medicine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Spinal Muscular Atrophy Medicine
13.3 Spinal Muscular Atrophy Medicine Production Process
13.4 Spinal Muscular Atrophy Medicine Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Spinal Muscular Atrophy Medicine Typical Distributors
14.3 Spinal Muscular Atrophy Medicine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Spinal Muscular Atrophy Medicine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Spinal Muscular Atrophy Medicine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Astellas Pharma Inc. Major Business
Table 5. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 6. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Astellas Pharma Inc. Recent Developments/Updates
Table 8. AveXis, Inc. Basic Information, Manufacturing Base and Competitors
Table 9. AveXis, Inc. Major Business
Table 10. AveXis, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 11. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. AveXis, Inc. Recent Developments/Updates
Table 13. Bioblast Pharma Ltd. Basic Information, Manufacturing Base and Competitors
Table 14. Bioblast Pharma Ltd. Major Business
Table 15. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 16. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Bioblast Pharma Ltd. Recent Developments/Updates
Table 18. Cytokinetics, Inc. 24 Basic Information, Manufacturing Base and Competitors
Table 19. Cytokinetics, Inc. 24 Major Business
Table 20. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product and Services
Table 21. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Cytokinetics, Inc. 24 Recent Developments/Updates
Table 23. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 24. F. Hoffmann-La Roche Ltd. Major Business
Table 25. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 26. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 28. Genethon Basic Information, Manufacturing Base and Competitors
Table 29. Genethon Major Business
Table 30. Genethon Spinal Muscular Atrophy Medicine Product and Services
Table 31. Genethon Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Genethon Recent Developments/Updates
Table 33. Genzyme Corporation Basic Information, Manufacturing Base and Competitors
Table 34. Genzyme Corporation Major Business
Table 35. Genzyme Corporation Spinal Muscular Atrophy Medicine Product and Services
Table 36. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Genzyme Corporation Recent Developments/Updates
Table 38. GMP-Orphan SAS Basic Information, Manufacturing Base and Competitors
Table 39. GMP-Orphan SAS Major Business
Table 40. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product and Services
Table 41. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. GMP-Orphan SAS Recent Developments/Updates
Table 43. Ionis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Ionis Pharmaceuticals, Inc. Major Business
Table 45. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 46. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Ionis Pharmaceuticals, Inc. Recent Developments/Updates
Table 48. Longevity Biotech, Inc Basic Information, Manufacturing Base and Competitors
Table 49. Longevity Biotech, Inc Major Business
Table 50. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product and Services
Table 51. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Longevity Biotech, Inc Recent Developments/Updates
Table 53. Neurodyn Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Neurodyn Inc. Major Business
Table 55. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 56. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Neurodyn Inc. Recent Developments/Updates
Table 58. Neurotune AG Basic Information, Manufacturing Base and Competitors
Table 59. Neurotune AG Major Business
Table 60. Neurotune AG Spinal Muscular Atrophy Medicine Product and Services
Table 61. Neurotune AG Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Neurotune AG Recent Developments/Updates
Table 63. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 64. Novartis AG Major Business
Table 65. Novartis AG Spinal Muscular Atrophy Medicine Product and Services
Table 66. Novartis AG Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Novartis AG Recent Developments/Updates
Table 68. Sarepta Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 69. Sarepta Therapeutics, Inc. Major Business
Table 70. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 71. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 72. Sarepta Therapeutics, Inc. Recent Developments/Updates
Table 73. Voyager Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 74. Voyager Therapeutics, Inc. Major Business
Table 75. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 76. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Voyager Therapeutics, Inc. Recent Developments/Updates
Table 78. Vybion, Inc. Basic Information, Manufacturing Base and Competitors
Table 79. Vybion, Inc. Major Business
Table 80. Vybion, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 81. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 82. Vybion, Inc. Recent Developments/Updates
Table 83. WAVE Life Sciences Ltd. Basic Information, Manufacturing Base and Competitors
Table 84. WAVE Life Sciences Ltd. Major Business
Table 85. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 86. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 87. WAVE Life Sciences Ltd. Recent Developments/Updates
Table 88. Global Spinal Muscular Atrophy Medicine Sales Quantity by Manufacturer (2019-2024) & (K Pcs)
Table 89. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2019-2024) & (USD Million)
Table 90. Global Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2019-2024) & (USD/Pcs)
Table 91. Market Position of Manufacturers in Spinal Muscular Atrophy Medicine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 92. Head Office and Spinal Muscular Atrophy Medicine Production Site of Key Manufacturer
Table 93. Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
Table 94. Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
Table 95. Spinal Muscular Atrophy Medicine New Market Entrants and Barriers to Market Entry
Table 96. Spinal Muscular Atrophy Medicine Mergers, Acquisition, Agreements, and Collaborations
Table 97. Global Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2024) & (K Pcs)
Table 98. Global Spinal Muscular Atrophy Medicine Sales Quantity by Region (2025-2030) & (K Pcs)
Table 99. Global Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2024) & (USD Million)
Table 100. Global Spinal Muscular Atrophy Medicine Consumption Value by Region (2025-2030) & (USD Million)
Table 101. Global Spinal Muscular Atrophy Medicine Average Price by Region (2019-2024) & (USD/Pcs)
Table 102. Global Spinal Muscular Atrophy Medicine Average Price by Region (2025-2030) & (USD/Pcs)
Table 103. Global Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 104. Global Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 105. Global Spinal Muscular Atrophy Medicine Consumption Value by Type (2019-2024) & (USD Million)
Table 106. Global Spinal Muscular Atrophy Medicine Consumption Value by Type (2025-2030) & (USD Million)
Table 107. Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2024) & (USD/Pcs)
Table 108. Global Spinal Muscular Atrophy Medicine Average Price by Type (2025-2030) & (USD/Pcs)
Table 109. Global Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 110. Global Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 111. Global Spinal Muscular Atrophy Medicine Consumption Value by Application (2019-2024) & (USD Million)
Table 112. Global Spinal Muscular Atrophy Medicine Consumption Value by Application (2025-2030) & (USD Million)
Table 113. Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2024) & (USD/Pcs)
Table 114. Global Spinal Muscular Atrophy Medicine Average Price by Application (2025-2030) & (USD/Pcs)
Table 115. North America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 116. North America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 117. North America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 118. North America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 119. North America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2024) & (K Pcs)
Table 120. North America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2025-2030) & (K Pcs)
Table 121. North America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2024) & (USD Million)
Table 122. North America Spinal Muscular Atrophy Medicine Consumption Value by Country (2025-2030) & (USD Million)
Table 123. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 124. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 125. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 126. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 127. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2024) & (K Pcs)
Table 128. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Country (2025-2030) & (K Pcs)
Table 129. Europe Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2024) & (USD Million)
Table 130. Europe Spinal Muscular Atrophy Medicine Consumption Value by Country (2025-2030) & (USD Million)
Table 131. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 132. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 133. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 134. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 135. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2024) & (K Pcs)
Table 136. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Region (2025-2030) & (K Pcs)
Table 137. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2024) & (USD Million)
Table 138. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value by Region (2025-2030) & (USD Million)
Table 139. South America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 140. South America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 141. South America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 142. South America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 143. South America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2024) & (K Pcs)
Table 144. South America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2025-2030) & (K Pcs)
Table 145. South America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2024) & (USD Million)
Table 146. South America Spinal Muscular Atrophy Medicine Consumption Value by Country (2025-2030) & (USD Million)
Table 147. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 148. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 149. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 150. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 151. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2024) & (K Pcs)
Table 152. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Region (2025-2030) & (K Pcs)
Table 153. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2024) & (USD Million)
Table 154. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value by Region (2025-2030) & (USD Million)
Table 155. Spinal Muscular Atrophy Medicine Raw Material
Table 156. Key Manufacturers of Spinal Muscular Atrophy Medicine Raw Materials
Table 157. Spinal Muscular Atrophy Medicine Typical Distributors
Table 158. Spinal Muscular Atrophy Medicine Typical Customers
Table 1. Global Spinal Muscular Atrophy Medicine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Spinal Muscular Atrophy Medicine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Astellas Pharma Inc. Major Business
Table 5. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 6. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Astellas Pharma Inc. Recent Developments/Updates
Table 8. AveXis, Inc. Basic Information, Manufacturing Base and Competitors
Table 9. AveXis, Inc. Major Business
Table 10. AveXis, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 11. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. AveXis, Inc. Recent Developments/Updates
Table 13. Bioblast Pharma Ltd. Basic Information, Manufacturing Base and Competitors
Table 14. Bioblast Pharma Ltd. Major Business
Table 15. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 16. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Bioblast Pharma Ltd. Recent Developments/Updates
Table 18. Cytokinetics, Inc. 24 Basic Information, Manufacturing Base and Competitors
Table 19. Cytokinetics, Inc. 24 Major Business
Table 20. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product and Services
Table 21. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Cytokinetics, Inc. 24 Recent Developments/Updates
Table 23. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 24. F. Hoffmann-La Roche Ltd. Major Business
Table 25. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 26. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 28. Genethon Basic Information, Manufacturing Base and Competitors
Table 29. Genethon Major Business
Table 30. Genethon Spinal Muscular Atrophy Medicine Product and Services
Table 31. Genethon Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Genethon Recent Developments/Updates
Table 33. Genzyme Corporation Basic Information, Manufacturing Base and Competitors
Table 34. Genzyme Corporation Major Business
Table 35. Genzyme Corporation Spinal Muscular Atrophy Medicine Product and Services
Table 36. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Genzyme Corporation Recent Developments/Updates
Table 38. GMP-Orphan SAS Basic Information, Manufacturing Base and Competitors
Table 39. GMP-Orphan SAS Major Business
Table 40. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product and Services
Table 41. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. GMP-Orphan SAS Recent Developments/Updates
Table 43. Ionis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Ionis Pharmaceuticals, Inc. Major Business
Table 45. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 46. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Ionis Pharmaceuticals, Inc. Recent Developments/Updates
Table 48. Longevity Biotech, Inc Basic Information, Manufacturing Base and Competitors
Table 49. Longevity Biotech, Inc Major Business
Table 50. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product and Services
Table 51. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Longevity Biotech, Inc Recent Developments/Updates
Table 53. Neurodyn Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Neurodyn Inc. Major Business
Table 55. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 56. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Neurodyn Inc. Recent Developments/Updates
Table 58. Neurotune AG Basic Information, Manufacturing Base and Competitors
Table 59. Neurotune AG Major Business
Table 60. Neurotune AG Spinal Muscular Atrophy Medicine Product and Services
Table 61. Neurotune AG Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Neurotune AG Recent Developments/Updates
Table 63. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 64. Novartis AG Major Business
Table 65. Novartis AG Spinal Muscular Atrophy Medicine Product and Services
Table 66. Novartis AG Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Novartis AG Recent Developments/Updates
Table 68. Sarepta Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 69. Sarepta Therapeutics, Inc. Major Business
Table 70. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 71. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 72. Sarepta Therapeutics, Inc. Recent Developments/Updates
Table 73. Voyager Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 74. Voyager Therapeutics, Inc. Major Business
Table 75. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 76. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Voyager Therapeutics, Inc. Recent Developments/Updates
Table 78. Vybion, Inc. Basic Information, Manufacturing Base and Competitors
Table 79. Vybion, Inc. Major Business
Table 80. Vybion, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 81. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 82. Vybion, Inc. Recent Developments/Updates
Table 83. WAVE Life Sciences Ltd. Basic Information, Manufacturing Base and Competitors
Table 84. WAVE Life Sciences Ltd. Major Business
Table 85. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 86. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 87. WAVE Life Sciences Ltd. Recent Developments/Updates
Table 88. Global Spinal Muscular Atrophy Medicine Sales Quantity by Manufacturer (2019-2024) & (K Pcs)
Table 89. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2019-2024) & (USD Million)
Table 90. Global Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2019-2024) & (USD/Pcs)
Table 91. Market Position of Manufacturers in Spinal Muscular Atrophy Medicine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 92. Head Office and Spinal Muscular Atrophy Medicine Production Site of Key Manufacturer
Table 93. Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
Table 94. Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
Table 95. Spinal Muscular Atrophy Medicine New Market Entrants and Barriers to Market Entry
Table 96. Spinal Muscular Atrophy Medicine Mergers, Acquisition, Agreements, and Collaborations
Table 97. Global Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2024) & (K Pcs)
Table 98. Global Spinal Muscular Atrophy Medicine Sales Quantity by Region (2025-2030) & (K Pcs)
Table 99. Global Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2024) & (USD Million)
Table 100. Global Spinal Muscular Atrophy Medicine Consumption Value by Region (2025-2030) & (USD Million)
Table 101. Global Spinal Muscular Atrophy Medicine Average Price by Region (2019-2024) & (USD/Pcs)
Table 102. Global Spinal Muscular Atrophy Medicine Average Price by Region (2025-2030) & (USD/Pcs)
Table 103. Global Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 104. Global Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 105. Global Spinal Muscular Atrophy Medicine Consumption Value by Type (2019-2024) & (USD Million)
Table 106. Global Spinal Muscular Atrophy Medicine Consumption Value by Type (2025-2030) & (USD Million)
Table 107. Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2024) & (USD/Pcs)
Table 108. Global Spinal Muscular Atrophy Medicine Average Price by Type (2025-2030) & (USD/Pcs)
Table 109. Global Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 110. Global Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 111. Global Spinal Muscular Atrophy Medicine Consumption Value by Application (2019-2024) & (USD Million)
Table 112. Global Spinal Muscular Atrophy Medicine Consumption Value by Application (2025-2030) & (USD Million)
Table 113. Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2024) & (USD/Pcs)
Table 114. Global Spinal Muscular Atrophy Medicine Average Price by Application (2025-2030) & (USD/Pcs)
Table 115. North America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 116. North America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 117. North America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 118. North America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 119. North America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2024) & (K Pcs)
Table 120. North America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2025-2030) & (K Pcs)
Table 121. North America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2024) & (USD Million)
Table 122. North America Spinal Muscular Atrophy Medicine Consumption Value by Country (2025-2030) & (USD Million)
Table 123. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 124. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 125. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 126. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 127. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2024) & (K Pcs)
Table 128. Europe Spinal Muscular Atrophy Medicine Sales Quantity by Country (2025-2030) & (K Pcs)
Table 129. Europe Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2024) & (USD Million)
Table 130. Europe Spinal Muscular Atrophy Medicine Consumption Value by Country (2025-2030) & (USD Million)
Table 131. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 132. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 133. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 134. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 135. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2024) & (K Pcs)
Table 136. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity by Region (2025-2030) & (K Pcs)
Table 137. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2024) & (USD Million)
Table 138. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value by Region (2025-2030) & (USD Million)
Table 139. South America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 140. South America Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 141. South America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 142. South America Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 143. South America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2019-2024) & (K Pcs)
Table 144. South America Spinal Muscular Atrophy Medicine Sales Quantity by Country (2025-2030) & (K Pcs)
Table 145. South America Spinal Muscular Atrophy Medicine Consumption Value by Country (2019-2024) & (USD Million)
Table 146. South America Spinal Muscular Atrophy Medicine Consumption Value by Country (2025-2030) & (USD Million)
Table 147. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Type (2019-2024) & (K Pcs)
Table 148. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Type (2025-2030) & (K Pcs)
Table 149. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Application (2019-2024) & (K Pcs)
Table 150. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Application (2025-2030) & (K Pcs)
Table 151. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Region (2019-2024) & (K Pcs)
Table 152. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity by Region (2025-2030) & (K Pcs)
Table 153. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value by Region (2019-2024) & (USD Million)
Table 154. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value by Region (2025-2030) & (USD Million)
Table 155. Spinal Muscular Atrophy Medicine Raw Material
Table 156. Key Manufacturers of Spinal Muscular Atrophy Medicine Raw Materials
Table 157. Spinal Muscular Atrophy Medicine Typical Distributors
Table 158. Spinal Muscular Atrophy Medicine Typical Customers
LIST OF FIGURES
Figure 1. Spinal Muscular Atrophy Medicine Picture
Figure 2. Global Spinal Muscular Atrophy Medicine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Type in 2023
Figure 4. LMI-070 Examples
Figure 5. ND-602 Examples
Figure 6. NT-1654 Examples
Figure 7. Nusinersen Examples
Figure 8. NXD-30001 Examples
Figure 9. Others Examples
Figure 10. Global Spinal Muscular Atrophy Medicine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 11. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Application in 2023
Figure 12. Hospital Examples
Figure 13. Clinic Examples
Figure 14. Others Examples
Figure 15. Global Spinal Muscular Atrophy Medicine Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 16. Global Spinal Muscular Atrophy Medicine Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 17. Global Spinal Muscular Atrophy Medicine Sales Quantity (2019-2030) & (K Pcs)
Figure 18. Global Spinal Muscular Atrophy Medicine Average Price (2019-2030) & (USD/Pcs)
Figure 19. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Manufacturer in 2023
Figure 20. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Manufacturer in 2023
Figure 21. Producer Shipments of Spinal Muscular Atrophy Medicine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 22. Top 3 Spinal Muscular Atrophy Medicine Manufacturer (Consumption Value) Market Share in 2023
Figure 23. Top 6 Spinal Muscular Atrophy Medicine Manufacturer (Consumption Value) Market Share in 2023
Figure 24. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Region (2019-2030)
Figure 25. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Region (2019-2030)
Figure 26. North America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 27. Europe Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 28. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 29. South America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 30. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 31. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 32. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Type (2019-2030)
Figure 33. Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2030) & (USD/Pcs)
Figure 34. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 35. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Application (2019-2030)
Figure 36. Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2030) & (USD/Pcs)
Figure 37. North America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 38. North America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 39. North America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Country (2019-2030)
Figure 40. North America Spinal Muscular Atrophy Medicine Consumption Value Market Share by Country (2019-2030)
Figure 41. United States Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Canada Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Mexico Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. Europe Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 45. Europe Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 46. Europe Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Country (2019-2030)
Figure 47. Europe Spinal Muscular Atrophy Medicine Consumption Value Market Share by Country (2019-2030)
Figure 48. Germany Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. France Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. United Kingdom Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Russia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Italy Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 54. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 55. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Region (2019-2030)
Figure 56. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value Market Share by Region (2019-2030)
Figure 57. China Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Japan Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Korea Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. India Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Southeast Asia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Australia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. South America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 64. South America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 65. South America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Country (2019-2030)
Figure 66. South America Spinal Muscular Atrophy Medicine Consumption Value Market Share by Country (2019-2030)
Figure 67. Brazil Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 68. Argentina Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 70. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 71. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Region (2019-2030)
Figure 72. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value Market Share by Region (2019-2030)
Figure 73. Turkey Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Egypt Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Saudi Arabia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. South Africa Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. Spinal Muscular Atrophy Medicine Market Drivers
Figure 78. Spinal Muscular Atrophy Medicine Market Restraints
Figure 79. Spinal Muscular Atrophy Medicine Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2023
Figure 82. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 83. Spinal Muscular Atrophy Medicine Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
Figure 1. Spinal Muscular Atrophy Medicine Picture
Figure 2. Global Spinal Muscular Atrophy Medicine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Type in 2023
Figure 4. LMI-070 Examples
Figure 5. ND-602 Examples
Figure 6. NT-1654 Examples
Figure 7. Nusinersen Examples
Figure 8. NXD-30001 Examples
Figure 9. Others Examples
Figure 10. Global Spinal Muscular Atrophy Medicine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 11. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Application in 2023
Figure 12. Hospital Examples
Figure 13. Clinic Examples
Figure 14. Others Examples
Figure 15. Global Spinal Muscular Atrophy Medicine Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 16. Global Spinal Muscular Atrophy Medicine Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 17. Global Spinal Muscular Atrophy Medicine Sales Quantity (2019-2030) & (K Pcs)
Figure 18. Global Spinal Muscular Atrophy Medicine Average Price (2019-2030) & (USD/Pcs)
Figure 19. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Manufacturer in 2023
Figure 20. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Manufacturer in 2023
Figure 21. Producer Shipments of Spinal Muscular Atrophy Medicine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 22. Top 3 Spinal Muscular Atrophy Medicine Manufacturer (Consumption Value) Market Share in 2023
Figure 23. Top 6 Spinal Muscular Atrophy Medicine Manufacturer (Consumption Value) Market Share in 2023
Figure 24. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Region (2019-2030)
Figure 25. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Region (2019-2030)
Figure 26. North America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 27. Europe Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 28. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 29. South America Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 30. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value (2019-2030) & (USD Million)
Figure 31. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 32. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Type (2019-2030)
Figure 33. Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2030) & (USD/Pcs)
Figure 34. Global Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 35. Global Spinal Muscular Atrophy Medicine Consumption Value Market Share by Application (2019-2030)
Figure 36. Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2030) & (USD/Pcs)
Figure 37. North America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 38. North America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 39. North America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Country (2019-2030)
Figure 40. North America Spinal Muscular Atrophy Medicine Consumption Value Market Share by Country (2019-2030)
Figure 41. United States Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Canada Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Mexico Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. Europe Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 45. Europe Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 46. Europe Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Country (2019-2030)
Figure 47. Europe Spinal Muscular Atrophy Medicine Consumption Value Market Share by Country (2019-2030)
Figure 48. Germany Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. France Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. United Kingdom Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Russia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Italy Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 54. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 55. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Region (2019-2030)
Figure 56. Asia-Pacific Spinal Muscular Atrophy Medicine Consumption Value Market Share by Region (2019-2030)
Figure 57. China Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Japan Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Korea Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. India Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Southeast Asia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Australia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. South America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 64. South America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 65. South America Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Country (2019-2030)
Figure 66. South America Spinal Muscular Atrophy Medicine Consumption Value Market Share by Country (2019-2030)
Figure 67. Brazil Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 68. Argentina Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Type (2019-2030)
Figure 70. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Application (2019-2030)
Figure 71. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Quantity Market Share by Region (2019-2030)
Figure 72. Middle East & Africa Spinal Muscular Atrophy Medicine Consumption Value Market Share by Region (2019-2030)
Figure 73. Turkey Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Egypt Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Saudi Arabia Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. South Africa Spinal Muscular Atrophy Medicine Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. Spinal Muscular Atrophy Medicine Market Drivers
Figure 78. Spinal Muscular Atrophy Medicine Market Restraints
Figure 79. Spinal Muscular Atrophy Medicine Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2023
Figure 82. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 83. Spinal Muscular Atrophy Medicine Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
